Evidence map›Paper›PMID 33113146›Full record

ReviewPharmacological reports : PR2020

Overview of the possible role of vitamin C in management of COVID-19.

Anis Abobaker, Aboubaker Alzwi, Alsalheen Hamed A Alraied

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pharmacological reports : PR, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed, 4 pooled it
16.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 4 syntheses or guidelines pooled it, 158 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Gut distress and interventionFrontiers in public health · 2023
    Pooled it
  4. Intravenous vitamin C use and risk of severity and mortality in COVID-19: A systematic review and meta-analysis.Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition · 2022
    Pooled it
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Anis AbobakerSpire Fylde Coast Hospital, St Walburgas road, Blackpool, FY3 8BP, UK. anis.abobaker@nhs.net.ORCID http://orcid.org/0000-0002-2826-5962
Aboubaker Alzwi7th of October Hospital, Benghazi, Libya.
Alsalheen Hamed A AlraiedJomhorya Hospital, Benghazi, Libya.
University of Benghazi · LYBlackpool and The Fylde College · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The mainstay of management of coronavirus disease 2019 (COVID-19) is mainly supportive as to date there is no effective antiviral treatment, apart from remdesivir which has been approved by Food and Drug administration (FDA) for treatment of COVID-19, or vaccine. Supplementation with micronutrients, such as vitamins and minerals, has gained an increasing interest as part of the supportive management of COVID-19. Vitamin C levels in serum and leukocytes are depleted during the acute stage of infection owing to increased metabolic demands. High-dose vitamin C supplement helps to normalise both serum and leukocytes vitamin C levels. Vitamin C has multiple pharmacological characteristics, antiviral, anti-oxidant, anti-inflammatory and immunomodulatory effects, which make it a potential therapeutic option in management of COVID-19. The use of high dose of intravenous vitamin C for management of COVID-19 in China and the United Stated has shown promising results. There were no reported adverse reactions with the short-term use of high dose of vitamin C. Given the fact that vitamin C is cheap, available and safe drug with beneficial effects in management of viral infections and critically ill patients reported in previous clinical trials, it is sensible to add it to COVID-19 management protocol particularly if the current ongoing clinical trials testing the effect of vitamin C in management of COVID-19 show positive results.

Indexed as

COVID-19 Drug TreatmentAnimalsAntiviral AgentsAscorbic AcidCOVID-19Dietary SupplementsDose-Response Relationship, DrugHumansAntiviral AgentsAscorbic AcidBeneficial effectsCOVID-19ManagementSARS-CoV-2Vitamin C

Identifiers

PMID33113146
PMCPMC7592143
OpenAlexW3095347249

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.